Merck’s Durham Site Receives U.S. FDA Licensure for Varicella Bulk
Dateline City:
DURHAM, N.C.
Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to manufacture bulk varicella at the company’s site in Durham, N.C., for use in Merck’s vaccines to protect against chickenpox and shingles. The approval will enable the site to produce bulk varicella supply for the U.S. and help boost Merck’s overall global supply capabilities.
In 2010, the site was approved to produce finished chickenpox vaccines.
Language:
English
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more
Source: Merck.com - Corporate News - Category: Pharmaceuticals Authors: Maria.tortoreto at merck.com Tags: chickenpox durham herpes zoster john howell julie gerberding maurice r. hilleman Merck MMD MRK MSD pneumovax shingles varivax willie deese zostavax Vaccine News Corporate News Latest News Source Type: news